End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.79 CNY | -.--% | -3.43% | -15.96% |
May. 24 | North China Pharmaceutical's Unit Passes GMP Inspection | MT |
May. 17 | North China Pharmaceutical Unit Gets China Nod for Rabies Vaccine | MT |
Sales 2022 | 10.5B 1.45B | Sales 2023 | 10.12B 1.4B | Capitalization | 9.78B 1.35B |
---|---|---|---|---|---|
Net income 2022 | -689M -95.15M | Net income 2023 | 4M 552K | EV / Sales 2022 | 1.94 x |
Net Debt 2022 | 9.37B 1.29B | Net Debt 2023 | 10.16B 1.4B | EV / Sales 2023 | 1.97 x |
P/E ratio 2022 |
-15.9
x | P/E ratio 2023 |
1,900
x | Employees | 10,159 |
Yield 2022 * |
-
| Yield 2023 |
0.18% | Free-Float | 41.8% |
1 week | -3.43% | ||
1 month | -7.53% | ||
3 months | -3.43% | ||
6 months | -24.45% | ||
Current year | -15.96% |
Managers | Title | Age | Since |
---|---|---|---|
Xin Yan Liu
CEO | Chief Executive Officer | 54 | 18-08-27 |
Jian Jun Li
DFI | Director of Finance/CFO | 53 | 09-08-31 |
Suo Qing Zhang
BRD | Director/Board Member | 54 | 20-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Guang Cheng Pan
BRD | Director/Board Member | 75 | 19-05-21 |
De Min Zhou
BRD | Director/Board Member | 58 | 19-05-21 |
Ji Gang Xie
BRD | Director/Board Member | 51 | 21-04-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +3.86% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 4.79 | -.--% | 6,593,800 |
24-05-30 | 4.79 | -0.42% | 6,214,402 |
24-05-29 | 4.81 | -1.03% | 6,654,800 |
24-05-28 | 4.86 | -2.02% | 7,845,800 |
24-05-27 | 4.96 | -.--% | 8,468,118 |
End-of-day quote Shanghai S.E., May 30, 2024
More quotes1st Jan change | Capi. | |
---|---|---|
-15.96% | 1.13B | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- 600812 Stock